Earnings Feed
Start Free
Syndax Pharmaceuticals Inc·4

Feb 10, 8:59 AM ET

Goldan Keith A. 4

Research Summary

AI-generated summary

Updated

Syndax (SNDX) CFO Keith Goldan Sells 3,410 Shares

What Happened

Keith A. Goldan, Chief Financial Officer of Syndax Pharmaceuticals (SNDX), reported a sale of 3,410 shares on 2026-02-09 at $21.03 per share, generating proceeds of $71,705. The filing indicates the sale was to satisfy tax withholding obligations associated with the vesting of restricted stock units (RSUs), a routine administrative sale rather than a market-timing purchase.

Key Details

  • Transaction date: 2026-02-09; Filing date: 2026-02-10 (SEC accession 0001193125-26-043813).
  • Transaction type: Sale (reported as open market or private sale).
  • Shares sold: 3,410 at $21.03 each; proceeds ≈ $71,705.
  • Footnote: Sale was to cover tax withholding tied to RSU vesting (footnote F1).
  • Shares owned after transaction: Not disclosed in the provided filing excerpt.
  • Timeliness: Filed the day after the transaction; not indicated as late.

Context

Sales to cover tax withholding when RSUs vest are common and typically administrative. Such transactions generally do not imply the insider is reducing conviction in the company; they simply satisfy tax obligations from equity compensation.